We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
+12.71%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$288M
AUM Growth
+$62.2M
(+28%)
Cap. Flow
+$51.4M
Cap. Flow
% of AUM
17.83%
Top 10 Holdings %
Top 10 Hldgs %
93.17%
Holding
15
New
1
Increased
5
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$8.89M |
| 2 |
ProQR Therapeutics
PRQR
|
+$3.09M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$2.97M |
| 4 |
Spero Therapeutics
SPRO
|
+$1.2M |
| 5 |
PVLA
Palvella Therapeutics
PVLA
|
+$899K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$9.33M |
| 2 |
SYBX
Synlogic
SYBX
|
+$2.87M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$2.45M |
| 4 |
Fate Therapeutics
FATE
|
+$1.71M |
| 5 |
MRUS
Merus
MRUS
|
+$1.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares Biotechnology ETF
IBB
$9.71B
| $109M | 37.87% |
1,000,000
+500,000
| +100% | +$53.2M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $43.9M | 15.22% |
500,000
| – | – |
|
3
uniQure
QURE
$3.22B
| $28.5M | 9.89% |
364,596
| – | – |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $20.4M | 7.08% |
1,391,497
-100,000
| -7% | -$1.42M |
|
|
5
Arrowhead Research
ARWR
$12.4B
| $14.8M | 5.13% |
557,455
-425,000
| -43% | -$9.33M |
|
|
6
Spero Therapeutics
SPRO
$73M
| $13.3M | 4.61% |
1,154,356
+100,000
| +9% | +$1.2M |
|
|
7
Fate Therapeutics
FATE
$326M
| $12.2M | 4.24% |
602,096
-95,000
| -14% | -$1.71M |
|
|
SYBX
8
DELISTED
Synlogic
SYBX
| $9.5M | 3.3% |
69,595
-23,539
| -25% | -$2.87M |
|
9
Xenon Pharmaceuticals
XENE
$6.12B
| $9.38M | 3.26% |
951,527
| – | – |
|
|
BCYC
10
Bicycle Therapeutics
BCYC
$292M
| $7.42M | 2.58% |
+737,529
| New | +$8.89M |
|
|
PVLA
11
Palvella Therapeutics
PVLA
$2.27B
| $6.82M | 2.37% |
18,148
+3,013
| +20% | +$899K |
|
|
12
ProQR Therapeutics
PRQR
$265M
| $6.82M | 2.37% |
748,861
+262,163
| +54% | +$3.09M |
|
|
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
| $6.04M | 2.1% |
46,840
+25,000
| +114% | +$2.97M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| – | – |
-30,618
| Closed | -$2.45M |
|
15
CytomX Therapeutics
CTMX
$754M
| – | – |
-101,767
| Closed | -$1.09M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Aquilo Capital Management held 15 positions worth $288M, up 28% from $226M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Aquilo Capital Management deployed $51.4M of net new capital in Q2 2019, opening 1 new position and adding to 5 existing holdings. Its largest new stake was Bicycle Therapeutics: 737,529 shares worth $7.42M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 55% a quarter earlier.
On the sell side, the largest reduction was Arrowhead Research, an estimated $9.33M trimmed.
- Aquilo Capital Management's largest Q2 2019 buy was Bicycle Therapeutics: 737,529 shares worth $7.42M.
- Aquilo Capital Management added most to ProQR Therapeutics in Q2 2019, an estimated $3.09M increase.
- Aquilo Capital Management's biggest Q2 2019 reduction was Arrowhead Research, cutting an estimated $9.33M.
- Aquilo Capital Management fully exited Blueprint Medicines in Q2 2019, selling an estimated $2.45M.
- Aquilo Capital Management's ten largest holdings make up 93% of its $288M portfolio in Q2 2019.
- Aquilo Capital Management opened 1 new position and closed 2 in Q2 2019.
- Aquilo Capital Management's portfolio value rose 28% quarter-over-quarter to $288M.
Based on Aquilo Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.